Diabetes is a global health crisis. According to the WHO (World Health Organization), there are about half a billion people worldwide suffering from diabetes. In 1980, the global numbers for people over 18 suffering from diabetes was 4.7%, and by 2014 the ratio had almost doubled (8.5%). The costs are high: Diabetes is a major cause of blindness, kidney failure, heart attacks, stroke, and lower limb amputation.
Not surprisingly, it’s big business. As of 2018, a single provider of dialysis centers, DaVita, operated 2,625 U.S. outpatient dialysis centers. Starbucks has 14,000 U.S. locations. Let that sink in. Starbucks locations only outnumber one provider’s dialysis facilities by slightly more than 5:1.
Dr. Luigi Vorluni, PhD, Head of Science and Physiology for NuroKor BioMedical – London, takes an exciting look at the role new applications for bioelectronics are playing in type 2 diabetes management. Dr. Vorluni research indicates that neuromuscular stimulation, especially among sedentary patients with combatting postprandial hyperglycaemia demonstrated significantly improved postprandial glucose levels, compared with control.
Given that postprandial hyperglycaemia is associated with mortality from diabetes complications and cardiovascular diseases, the results from this study have massive potential for prevention.